Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Increases speed to market for drug developers working on nucleic acid therapeutics
Acquisition expands high-value medical platform
Exploring new opportunities within the fast-growing market of microfluidics
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Subscribe To Our Newsletter & Stay Updated
